187 related articles for article (PubMed ID: 11486010)
1. Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.
Peretti M; Villard J; Barras E; Zufferey M; Reith W
Mol Cell Biol; 2001 Sep; 21(17):5699-709. PubMed ID: 11486010
[TBL] [Abstract][Full Text] [Related]
2. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
[TBL] [Abstract][Full Text] [Related]
3. Multiple interactions between BRG1 and MHC class II promoter binding proteins.
Mudhasani R; Fontes JD
Mol Immunol; 2005 Apr; 42(6):673-82. PubMed ID: 15781111
[TBL] [Abstract][Full Text] [Related]
4. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.
Karosiene E; Rasmussen M; Blicher T; Lund O; Buus S; Nielsen M
Immunogenetics; 2013 Oct; 65(10):711-24. PubMed ID: 23900783
[TBL] [Abstract][Full Text] [Related]
5. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
Masternak K; Reith W
EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
[TBL] [Abstract][Full Text] [Related]
6. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
7. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
[TBL] [Abstract][Full Text] [Related]
8. A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y.
Villard J; Peretti M; Masternak K; Barras E; Caretti G; Mantovani R; Reith W
Mol Cell Biol; 2000 May; 20(10):3364-76. PubMed ID: 10779326
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of MHCII genes by PRMT6, via an AT-hook motif of RFX5.
Stavride P; Arampatzi P; Papamatheakis J
Mol Immunol; 2013 Dec; 56(4):390-8. PubMed ID: 23911394
[TBL] [Abstract][Full Text] [Related]
10. Mapping of the interaction site of the defective transcription factor in the class II major histocompatibility complex mutant cell line clone-13 to the divergent X2-box.
Ono SJ; Song Z
J Biol Chem; 1995 Mar; 270(11):6396-402. PubMed ID: 7890777
[TBL] [Abstract][Full Text] [Related]
11. The bare lymphocyte syndrome and the regulation of MHC expression.
Reith W; Mach B
Annu Rev Immunol; 2001; 19():331-73. PubMed ID: 11244040
[TBL] [Abstract][Full Text] [Related]
12. The transcription factor RFX protects MHC class II genes against epigenetic silencing by DNA methylation.
Seguín-Estévez Q; De Palma R; Krawczyk M; Leimgruber E; Villard J; Picard C; Tagliamacco A; Abbate G; Gorski J; Nocera A; Reith W
J Immunol; 2009 Aug; 183(4):2545-53. PubMed ID: 19620312
[TBL] [Abstract][Full Text] [Related]
13. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression.
Waldburger JM; Masternak K; Muhlethaler-Mottet A; Villard J; Peretti M; Landmann S; Reith W
Immunol Rev; 2000 Dec; 178():148-65. PubMed ID: 11213800
[TBL] [Abstract][Full Text] [Related]
14. Assembly of the RFX complex on the MHCII promoter: role of RFXAP and RFXB in relieving autoinhibition of RFX5.
Garvie CW; Boss JM
Biochim Biophys Acta; 2008 Dec; 1779(12):797-804. PubMed ID: 18723135
[TBL] [Abstract][Full Text] [Related]
15. Mutation in the class II trans-activator leading to a mild immunodeficiency.
Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
[TBL] [Abstract][Full Text] [Related]
16. Direct genetic correction as a new method for diagnosis and molecular characterization of MHC class II deficiency.
Matheux F; Ikinciogullari A; Zapata DA; Barras E; Zufferey M; Dogu F; Regueiro JR; Reith W; Villard J
Mol Ther; 2002 Dec; 6(6):824-9. PubMed ID: 12498778
[TBL] [Abstract][Full Text] [Related]
17. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator.
Douhan J; Lieberson R; Knoll JH; Zhou H; Glimcher LH
J Exp Med; 1997 Jun; 185(11):1885-95. PubMed ID: 9166418
[TBL] [Abstract][Full Text] [Related]
18. Two B cell factors bind the HLA-DRA X box region and recognize different subsets of HLA class II promoters.
Hasegawa SL; Boss JM
Nucleic Acids Res; 1991 Nov; 19(22):6269-76. PubMed ID: 1956787
[TBL] [Abstract][Full Text] [Related]
19. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
[TBL] [Abstract][Full Text] [Related]
20. An isotype-specific trans-acting factor is defective in a mutant B cell line that expresses HLA-DQ, but not -DR or -DP.
Ono SJ; Bazil V; Sugawara M; Strominger JL
J Exp Med; 1991 Mar; 173(3):629-37. PubMed ID: 1997650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
